ISSN: 2476-2024

Diagnostic Pathology: Open Access
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Research Article   
  • Diagn Pathol Open
  • DOI: 10.4172/ 2476-2024.7.S12.003

Keloid-specific Gene Expression Profiling for Accurate Diagnostic and Therapeutic Applications

Yoojeong Oh4, Jaemyun Lyu2,7, Karthika Muthuramalingam2, Eunmyong Lee3, Miae Choi1, Insuk Sohn2, Jong-Hee Lee5 and Seok-Hyung Kim1,4,6*
1Department of Pathology, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
2Arontier Inc., Seoul, Republic of Korea
3InnoCure Therapeutics Inc., Seoul, Republic of Korea
4Department of Health Science and Technology, Sungkyunkwan University, Seoul, Republic of Korea
5Department of Dermatology, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
6Single Cell Network Research Center, Suwon, Republic of Korea
7RNA Cell Biology Lab, Seoul, Republic of Korea
*Corresponding Author: Dr. Seok-Hyung Kim, Department of Health Science and Technology, Sungkyunkwan University, Seoul, Republic of Korea, Email: platoshkim@gmail.com

Received: 20-Oct-2022 / Manuscript No. DPO-22-77863 / Editor assigned: 21-Oct-2022 / PreQC No. DPO-22-77863 / Reviewed: 04-Nov-2022 / QC No. DPO-22-77863 / Revised: 14-Nov-2022 / Manuscript No. DPO-22-77863 / Accepted Date: 14-Nov-2022 / Published Date: 21-Nov-2022 DOI: 10.4172/ 2476-2024.7.S12.003

Abstract

Scars are a heterogeneous disease including normotrophic scars, hypertrophic scars, and keloids. Of these lesions, keloids are a distinct subtype from any other type of scar. Clinically, it causes pain, itching, or tenderness, causing life discomfort and characteristically irreversible.

Despite various treatment modalities, restoring keloids to normal tissues is difficult, and frequent recurrences have been reported. Therefore, it is essential to identify keloid-specific genes for accurate diagnosis and treatment of keloids. In an effort to find out keloid-specific genes, several studies compared keloids with scar-free normal skin, which leading general scar-related genes to be chosen rather than keloid-specific genes. To select for highly accurate keloid-specific genes and pathways, we compared the transcriptome profile of keloids with those of normotrophic scars and hypertrophic scars, which acquired from formalin-fixed paraffin-embedded human skin samples using high-throughput RNA-sequencing techniques. Differential expression analyses and over-representation analyses revealed that genes related to nervous system process were upregulated in keloids, whereas genes related with immune responses were downregulated in keloids. Additionally, the extracellular matrix related processes were highlighted in both hypertrophic scars and keloids. Finally, we highlight potential keloid-specific biomarkers and expression changes that can be employed for future therapeutics of keloids.

Keywords: Normotrophic scar; Hypertrophic scar; Keloid; RNA sequencing; Scar management

Introduction

A scar is an area of fibrous tissue that replaces normal skin after an injury. Scarring is a biological process of wound healing. Despite tremendous progress in unravelling the science behind wound healing, the mechanisms for elucidating scar formation caused by abnormal wound healing are still unknown [1]. Deep injury to the reticular dermis sometimes results in pathological abnormal fibrous scars such as hypertrophic scars and keloids, which are thought to be caused by abnormal wound healing due to altered gene expression in the wound healing tissue. Hypertrophic scars and keloids consist of numerous inflammatory cells, proliferating fibroblasts, progressive collagen deposition and enhanced angiogenesis [2-4]. And they present distinct clinical, histological, and developmental features. Clinically, hypertrophic scars are confined within the wound boundary, while keloids extend growth beyond the wound borders [5,6]. Histologically, hypertrophic scars have fewer thick collagen fibers than keloids [7,8]. Furthermore, hypertrophic scar tissues are composed of low-density Dermatan Sulfate (DS) proteoglycans, while keloid scar tissues are composed of both low-density DS and Chondroitin Sulfate (CS) proteoglycans, with CS proteoglycans in higher proportion [9,10]. Hypertrophic scars usually develop within two months from injury and tend to regress over time. In contrast, keloids develop and progress after 3 months or more, grow irreversibly for years, and cause medical problems as well as life problems such as itchiness and unusual appearance for patients [11]. Hypertrophic scars tend to respond well to treatment. On the other hand, once formed, keloids are very difficult to restore to normal tissues, and frequent recurrences and exacerbations over a long period of time become another obstacle to treatment [12]. It has not been reported yet what kind of scars would be occurred when the skin is damaged. Therefore, it is essential to understand the pathological factors behind the various scar types and gene expression profiles of pathological scars caused by abnormal wound healing, for the development of efficient treatment strategies for the treatment of abnormal scars.

To date, there have been five reports comparing gene expression patterns in keloid and related scar lesions using whole transcriptome analysis such as cDNA microarray or RNA-seq. Onoufriadis, et al. and Wu, et al. performed RNA-seq on keloids and normal skin tissue [13,14]. Hahn, et al. Chao-Kai, et al. and Matsumoto, et al. compared mRNA expression patterns between keloids and normal skin tissue using cDNA microarrays [15-17]. Although these studies have provided new insights into keloids, there are limitations in that the selected keloid- specific gene expression profile could not be distinguished from a scar- related genes expression profile, since they compared keloids to scar- free normal skin tissue not to reversible scars. Considering different responses of irreversible keloids and reversible hypertrophic scars to the treatment, it is crucial to compare the overall gene expression patterns of irreversible scars such as keloids and reversible scars. In this study, we aimed to compare the overall gene expression patterns of reversible and irreversible scars and provide insight into the molecular and cellular mechanisms behind these lesions. Toward this goal, high-throughput RNA-sequencing techniques using next-generation sequencing technology were employed. By elucidating highly specific genes and related signaling pathways for abnormal fibroproliferative scar lesions, this study can contribute to the development of effective and targeted therapeutic strategies for these lesions.

Materials and Methods

Results

Expression analysis of keloids and related lesions through RNA-seq

WTo reveal the gene expression characteristics of keloids and related lesions, we collected 4 keloid tissues, 5 hypertrophic scars, and 3 normotrophic scars. The three types of lesions were categorized by characteristic appearance, histological morphology and clinical features [26]. From normotrophic scars and hypertrophic scars to keloids, the epidermal cell layer becomes thicker and the collagen fibers become thicker and denser. Consistent with previous reports, keloids and hypertrophic scars showed abundant vasculature, high mesenchymal cell density, inflammatory cell infiltration, and thickened epidermal cell layer compared to normotrophic scars [27,28]. In particular, thick collagen fibers composed of numerous tightly packed fibrils were observed in keloids, while hypertrophic scars exhibit a nodular structure composed of fibroblasts, small blood vessels, and randomly organized collagen fibers [29].

To confirm the histopathologic classification of the samples, the expression profiles of these collected tissue samples were analyzed by unsupervised clustering using a machine learning-based dimensionality reduction algorithm such as MDS (Multi-Dimensional Scaling) and tSNE (t-Distributed Stochastic Neighbor Embedding). The results showed that these lesions were separated into three clusters, relatively consistent with their diagnoses. The differential genes of these normotrophic Scar (S), Hypertrophic Scar (HS), and Keloid (K) were grouped into 8 classes depending on expression pattern: ○1 UU (Up-Up, S<HS<K), ○2 UF (Up-Flat, S<HS~K), ○3 FD (Flat-Down, S~HS>K), ○4 UD (Up-Down, S<HS>K), ○5 DD (Down-Down, S>HS>K), ○6 DF (Down-Flat, S>HS~K), ○7 FU (Flat-Up, S~HS<K), and ○8 DU (Down-Up, S>HS<K). The genes were separated as upregulated (U), downregulated (D), or not differentially expressed (F). Expression pattern of grouped genes over scar types were also separated in patterns as expected (Figure 1) (Table 1).

diagnostic-pathology-normotrophic

Figure 1: Differences in the pathology and gene expression patterns of normotrophic scars, hypertrophic scars, and keloids. A. From normotrophic scars and hypertrophic scars to keloids, the epidermal cell layer becomes thicker and the collagen fibers become thicker and denser; B. MDS and tSNE clustering of 12 skin tissues. Tissues are color coded by an algorithm for determining expression clusters and tissue types; C. Heat map of gene expression grouped under different e xpression models across the three types of scars.

Type of tissue Gender and Age Body part effected
Normotrophic Scar #1 F 56 Skin, Scalp
Normotrophic Scar #2 F 57 Skin, back
Normotrophic Scar #3 F 35 Skin, public area
Hypertropic Scar #1 F 55 Skin, neck
Hypertropic Scar #2 M 69 Skin, right thigh
Hypertropic Scar #3 M 68 Skin, post-auricular area
Hypertropic Scar #4 F 81 Skin, right breast
Hypertropic Scar #5 M 66 Skin, left cheek
Keloid #1 F 21 Skin, ear
Keloid #2 F 19 Skin, ear
Keloid #3 F 53 Skin, abdomen
Keloid #4 M 15 Skin, ear

Table 1: Summary of information on scar tissues used in this study.

Derivation of keloid-specific genes and signaling pathways by comparing gene expression profiles of keloids and reversible scars

Once keloids were developed, they grow irreversibly for years, compared to normoptophic and hypertrophic scars which regress over time. In an attempt to discover genes specifically regulated in keloids as irreversible scars, we classified normotrophic and hypertrophic scars as one group-reversible scar and compared their gene expression profiles with that of keloids. To identify genes specifically up or downregulated in keloids, we performed mRNA sequencing and differential expression analysis on RNA-Seq data from normotrophic scars, hypertrophic scars, and keloids with following statistical methods. For differential expression analysis, we implemented Ensemble approaches as three widely used methods (Limma-voom, edgeR and DESeq2) to achieve lower false positive DEGs. In this approach, genes were flagged as DEG on at least two different analyses was used for further analysis. Overall, 195 genes were downregulated in keloids compared with reversible scars, whereas 306 genes were upregulated in keloids. Of these genes, golgin A6 family genes and ERICH6B (Glutamate-Rich 6B) genes were identified as the most significantly changed genes as described in volcano plots. It should be noted that the levels of golgin A6 family genes and ERICH6B genes were not only significantly changed, but also exhibited the highest magnitude of fold change among the genes in keloids compared with reversible scars. Golgins are a family of predominantly coiled-coil proteins that are localized to the Golgi apparatus [30]. Anchored to the Golgi membrane, they are predicted to project into the surrounding cytoplasm and are involved in various functions of the Golgi apparatus, such as vesicular traffic through golgin-mediated tethering. Second, golgins are involved in maintenance and positioning of the Golgi apparatus within cells. In addition to acting as tethers, some golgins can sequester various factors at the Golgi membrane, allowing spatiotemporal regulation of downstream cellular functions. However, the specific functions and clinical relevance of the Golgin A6 family has not been elucidated yet. In the case of ERICH6B, there is little information on the structure, function and clinical relevance of the gene, except for its predominant expression in the testis.

Next, up and downregulated 501 DEGs (up: 306, down: 195) was classified as expression changes on normotrophic scars-hypertrophic scars-keloids. Specifically, most of the downregulated DEGs in keloids belonged to the FD (Flat-Down, 64.6%) subgroup, in contrast to very few belonged to DD (Down-Down, 0%) or DF (Down-Flat, 5.6%) subgroup. On the other hand, most of upregulated DEGs in keloids belonged to the FU (Flat-Up, 67.3%) subgroup, while very few belonged to UU (Up-Up, 1.0%) or UF (Up-Flat, 1.0%) subgroup. These results indicate that most of the DEGs exhibited small differences between normotrophic and hypertrophic scars but were higher or lower in keloids.

For better understanding of biological function of genes that exhibited specifically high or low expression in keloids. DEGs are enriched to Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway. Over-representation analysis on GO Biological Process showed that the genes involved in ‘activation of immune response’, ‘antigen processing and presentation of peptide antigen’ and ‘immunoglobulin mediated immune response’ are significantly downregulated in keloids. These findings suggest that immune regulation and inflammatory mechanisms play important roles in keloid formation. On the other hand, DEGs upregulated in keloids were over-represented in roles of ‘sensory perception’, ‘neuron development’, and ‘muscle filament sliding’. Over-representation analysis on KEGG pathway demonstrated that downregulated DEGs in keloids were enriched in ‘systemic lupus erythematosus’ and ‘antigen processing and presentation’, whereas upregulated DEGs in keloids were enriched in ‘protein digestion and absorption’ and ‘insulin secretion’. Overall, downregulated DEGs in keloids were associated with immune functions, whereas upregulated DEGs in keloids were associated with neuron development and muscle contraction. In keloids, the regulation of T cell proliferation and negative regulation of T cell activation were specifically downregulated, whereas visual/sensory perception was specifically upregulated. In addition, the systemic lupus erythematosus pathway was downregulated, whereas the pathways of protein digestion and absorption were upregulated. (Figure 2) (Tables 2-5).

diagnostic-pathology-downregulated

Figure 2: Differentially expressed genes (DEGs) specifically upregulated and downregulated in keloids compared to normotrophic scars and hypertrophic scars. A and C. Venn diagrams represent the intersection of DEGs between keloid and reversible scars derived by three different methods (Limma-voom, DESeq2 and edgeR). Compared with keloid and reversible scars, downregulated DEGs were a total of 195, and upregulated DEGs were a total of 306; B. Volcano plot of DEGs showing the standardized mean difference and the adjusted p-value for the 501 genes; D. Downregulated DEGs in keloids compared to reversible scars can be divided into five patterns: DD (Down-Down), FD (Flat-Down), DF (Down-Flat), UD (Up-Down), FF (Flat-Flat); E. The five patterns of up-regulated DEG can be classified as follows: UU (Up-Up), FU (Flat-Up), UF (Up-Flat), DU (Down-Up), FF (Flat-Flat); F. Results of GO enrichment analysis and KEGG pathway classification enrichment analysis for keloids specific DEGs.

GO ID Term Overlap Adjusted P- value Genes
GO:0002253 Activation of immune response 20/487 0.000138 CD86, HLA-DRB5, FCER1G, CTSS, PYCARD, FCGR3A, FCGR2A, C3AR1, HLA-DPB1, CDK1, TLR8, HLA-DRA, CD36, VSIG4, PIK3AP1, FCGR1A, HLA-DRB1, CTSB, C1QC, HLA-DPA1
GO:0048002 Antigen processing and presentation of peptide antigen 12/185 0.000228 BCAP31, CD74, HLA-DRB5, FCER1G, HLA-DPB1, HLA-DRA, CD36, FCGR1A, HLA-DRB1, CTSS, PSMA7, HLA-DPA1
GO:0016064 Immunoglobulin mediated immune response 5/16 0.000228 CD74, FCER1G, TLR8, FCGR1A, HLA-DRB1
GO:0006954 Inflammatory response 16/376 0.000337 IL10, CCL13, CD163, SERPINA1, TNFAIP6, LY86, LYZ, AIF1, PYCARD, C3AR1, SPP1, BDKRB2, TLR8, CCL18, FCGR1A, HLA-DRB1
GO:0002478 Antigen processing and presentation of exogenous peptide antigen 11/171 0.000337 CD74, HLA-DRB5, FCER1G, HLA-DPB1, HLA-DRA, CD36, FCGR1A, HLA-DRB1, CTSS, PSMA7, HLA-DPA1
GO:0019884 Antigen processing and presentation of exogenous antigen 11/173 0.000337 CD74, HLA-DRB5, FCER1G, HLA-DPB1, HLA-DRA, CD36, FCGR1A, HLA-DRB1, CTSS, PSMA7, HLA-DPA1
GO:0019724 B-cell mediated immunity 5/20 0.000337 CD74, FCER1G, TLR8, FCGR1A, HLA-DRB1
GO:1903034 Regulation of response to wounding 15/347 0.000346 IL10, FCER1G, SCARA5, CMA1, CAV1, PLA2G7, F3, CTSS, FABP4, ALOX5AP, SPP1, CD36, PIK3AP1, FCGR1A, HLA-DRB1
GO:0002757 Immune response-activating signal transduction 17/440 0.000346 CD86, HLA-DRB5, FCER1G, CTSS, FCGR3A, FCGR2A, C3AR1, HLA-DPB1, CDK1, TLR8, HLA-DRA, CD36, PIK3AP1, FCGR1A, HLA-DRB1, CTSB, HLA-DPA1
GO:0050863 Regulation of T cell activation 13/259 0.000346 IL10, CD86, CD74, HLA-DRB5, CAV1, AIF1, PYCARD, HLA-DPB1, HLA-DRA, VSIG4, IL7R, HLA-DRB1, HLA-DPA1

Table 2: GO Biological Process enrichment result for down regulated DEGs in Keloid VS. Reversible Scars.

Term Overlap Adjusted P-value Genes
Systemic lupus erythematosus 25/133 3.21E-25 CD86, HIST1H2BM, HIST1H2BO, FCGR3A, HIST1H3A, HIST1H3H, HIST1H3B, FCGR1A, HIST1H2AB, HLA-DPA1, HIST1H2AM, IL10, HLA-DRB5, HIST1H4L, HIST1H2AJ, HIST1H4A, HIST1H4B, FCGR2A, HIST4H4, HLA-DPB1, HLA-DRA, HIST1H2BH, HIST1H4C, HLA-DRB1, C1QC
Staphylococcus aureus infection 12/68 2.37E-12 IL10, FCGR3A, HLA-DRB5, FCGR2A, C3AR1, HLA-DPB1, HLA-DRA, FPR3, FCGR1A, HLA-DRB1, HLA-DPA1, C1QC
Alcoholism 15/180 2.76E-10 HIST1H2AM, HIST1H2BM, HIST1H2BO, MAOB, HIST1H4L, HIST1H2AJ, HIST1H4A, HIST1H3A, HIST1H4B, HIST4H4, HIST1H2BH, HIST1H3H, HIST1H3B, HIST1H4C, HIST1H2AB
Antigen processing and presentation 10/77 3.83E-09 CD74, HLA-DRB5, HLA-DPB1, HLA-DRA, HSPA2, CTSS, HSPA1B, HLA-DRB1, CTSB, HLA-DPA1
Asthma 7/31 1.62E-08 IL10, HLA-DRB5, FCER1G, HLA-DPB1, HLA-DRA, HLA-DRB1, HLA-DPA1
Tuberculosis 13/179 2.33E-08 IL10, CD74, HLA-DRB5, FCER1G, CTSS, FCGR3A, FCGR2A, HLA-DPB1, HLA-DRA, FCGR1A, ATP6V0C, HLA-DRB1, HLA-DPA1
Phagosome 12/152 3.25E-08 MSR1, HLA-DRB5, FCGR3A, FCGR2A, HLA-DPB1, HLA-DRA, CD36, FCGR1A, ATP6V0C, HLA-DRB1, CTSS, HLA-DPA1
Leishmaniasis 9/74 4.23E-08 IL10, FCGR3A, HLA-DRB5, FCGR2A, HLA-DPB1, HLA-DRA, FCGR1A, HLA-DRB1, HLA-DPA1
Allograft rejection 7/38 7.35E-08 CD86, IL10, HLA-DRB5, HLA-DPB1, HLA-DRA, HLA-DRB1, HLA-DPA1
Intestinal immune network for IgA production 7/48 3.95E-07 CD86, IL10, HLA-DRB5, HLA-DPB1, HLA-DRA, HLA-DRB1, HLA-DPA1

Table 3: KEGG Pathway enrichment result for down regulated DEGs in Keloid VS. Reversible Scars.

GO ID Term Overlap Adjusted P-value Genes
GO:0050953 sensory perception of light stimulus 13/198 0.0111 TULP1, RPGR, COL1A1, RP1L1, OCLM, RIMS1, CACNB2, RP1, GRM8, SIX3, CNGB3, PPEF2, GPR179
GO:0007601 visual perception 13/195 0.0111 TULP1, RPGR, COL1A1, RP1L1, OCLM, RIMS1, CACNB2, RP1, GRM8, SIX3, CNGB3, PPEF2, GPR179
GO:0007600 sensory perception 20/457 0.017 TAS2R60, EYA1, COL11A2, CACNA1D, TULP1, SLC6A3, RPGR, COL1A1, RP1L1, OCLM, CACNB2, RIMS1, RP1, MYO15A, GRM8, SIX3, CNGB3, ASIC3, PPEF2, GPR179
GO:0031960 response to corticosteroid 10/140 0.0278 COL1A1, MSTN, UCN2, WNT7B, BCKDHB, PDX1, GRIK4, FOSB, FOS, SOX30
GO:0048666 neuron development 9/121 0.038 ALK, ROBO2, TMC1, RP1L1, RP1, TULP1, HOXD10, GLI2, RPGR
GO:0070588 calcium ion transmembrane transport 9/128 0.0487 TMC1, CACNB2, RYR2, CACNG8, IL1RAPL1, CACNA1B, CACNA1D, ATP2A1, TRPM4
GO:0033275 actin-myosin filament sliding 5/38 0.0551 MYH2, ACTN2, MYH8, MYH4, MYH7
GO:0030049 muscle filament sliding 5/38 0.0551 MYH2, ACTN2, MYH8, MYH4, MYH7
GO:0042391 regulation of membrane potential 13/266 0.0551 RYR2, KCNE2, ACTN2, CACNA1B, CACNA1D, GRIK2, RIMS1, NETO1, GJA5, CHRNE, CNGB3, TRPM4, SHANK1
GO:0007215 glutamate receptor signaling pathway 5/40 0.0634 GRM5, GRM8, GRIK4, GRIK2, CDK5R1

Table 4: GO Biological Process enrichment result for up regulated DEGs in Keloid VS. Reversible Scars.

Term Overlap Adjusted P-value Genes
Protein digestion and absorption 8/90 0.0125 COL1A1, COL27A1, MEP1B, COL22A1, COL7A1, COL11A2, ATP1B4, SLC16A10
Insulin secretion 6/86 0.0601 RYR2, CCKAR, PDX1, ATP1B4, CACNA1D, TRPM4
Primary bile acid biosynthesis 3/17 0.0601 CYP46A1, BAAT, CYP7A1
Cardiac muscle contraction 6/78 0.0601 RYR2, CACNB2, CACNG8, ATP1B4, CACNA1D, MYH7
Hypertrophic Cardiomyopathy (HCM) 6/85 0.0601 RYR2, CACNB2, CACNG8, ITGA2B, CACNA1D, MYH7
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) 6/72 0.0601 RYR2, CACNB2, CACNG8, ACTN2, ITGA2B, CACNA1D
Dilated Cardiomyopathy (DCM) 6/91 0.0685 RYR2, CACNB2, CACNG8, ITGA2B, CACNA1D, MYH7
Glutamatergic synapse 6/114 0.166 GRM5, GRM8, GRIK4, CACNA1D, GRIK2, SHANK1
Calcium signaling pathway 8/188 0.166 RYR2, GRM5, CCKAR, PLCZ1, CACNA1B, CACNA1D, ATP2A1, MYLK3
Taurine and hypotaurine metabolism 11/02 0.2 GADL1, BAAT

Table 5: KEGG Pathway enrichment result for up regulated DEGs in Keloid VS. Reversible Scar.

Keloids and hypertrophic specific upregulated DEGs are predominantly associated with remodeling of extracellular matrix structural tissue

Hypertrophic scars and keloids have a commonality in that they are present in abnormally high levels in fibroproliferative lesions. To gain insight into the mechanisms behind this abnormality, we attempted to identify DEGs that are specifically upregulated in hypertrophic scars and keloids. Our study revealed 88 upregulated genes in these exaggerated scars compared to normotrophic scars, including RYR2 (ryanodine receptor 2), ARMC3 (armadillo repeat including 3), and SMCO2 (single-pass membrane protein with coiled-coil domains 2) as representative genes with larger fold changes. Particularly, these 88 DEGs were highly over-represented on ‘extracellular structure/matrix organization’ among GO Biological Process terms. Overall, these results are in consistently implies that the clinical observation of excessive ECM depositions are represented in both hypertrophic scars and keloids (Tables 6 and 7).

GO ID Term Overlap Adjusted P-value Genes
GO:0043062 Extracellular structure organization 15/360 2.97E-08 ITGB1, POSTN, OLFML2B, TGFB3, PLOD2, NID2, GDF5, ADAMTS4, ACAN, MMP14, ADAMTS14, BMP1, ITGA10, SH3PXD2B, EMILIN1
GO:0030198 Extracellular matrix organization 15/359 2.97E-08 ITGB1, POSTN, OLFML2B, TGFB3, PLOD2, NID2, GDF5, ADAMTS4, ACAN, MMP14, ADAMTS14, BMP1, ITGA10, SH3PXD2B, EMILIN1
GO:0010975 Regulation of neuron projection development 9/275 0.00139 PTPRD, NTRK1, ITGB1, FRMD7, MAP1B, NCS1, NEFL, FAT3, EPHA3
GO:0001501 Skeletal system development 7/162 0.00206 ADAMTS4, ACAN, POSTN, BMP1, SH3PXD2B, ALPL, PAPSS2
GO:0031344 Regulation of cell projection organization 10/391 0.00206 PTPRD, NTRK1, ITGB1, FRMD7, TGFB3, MAP1B, NCS1, NEFL, FAT3, EPHA3
GO:0045664 Regulation of neuron differentiation 10/405 0.00233 PTPRD, NTRK1, ITGB1, FRMD7, MAP1B, NCS1, NEFL, FAT3, GDF5, EPHA3
GO:0031346 Positive regulation of cell projection organization 7/195 0.00427 PTPRD, NTRK1, ITGB1, TGFB3, MAP1B, NEFL, EPHA3
GO:0010720 Positive regulation of cell development 9/358 0.00428 PTPRD, NTRK1, ITGB1, TGFB3, MAP1B, SNAI1, NEFL, GDF5, EPHA3
GO:0010976 Positive regulation of neuron projection development 6/144 0.00562 PTPRD, NTRK1, ITGB1, MAP1B, NEFL, EPHA3
GO:0045666 Positive regulation of neuron differentiation 7/217 0.00562 PTPRD, NTRK1, ITGB1, MAP1B, NEFL, GDF5, EPHA3

Table 6: GO Biological Process enrichment result for UF pattern of DEGs.

Term Overlap Adjusted P-value Genes
Hypertrophic Cardiomyopathy (HCM) 4/85 0.0363 ITGB1, RYR2, TGFB3, ITGA10
Dilated Cardiomyopathy (DCM) 4/91 0.0363 ITGB1, RYR2, TGFB3, ITGA10
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) 3/72 0.137 ITGB1, RYR2, ITGA10
Amyotrophic Lateral Sclerosis (ALS) 2/51 0.476 NEFL, NEFH
Pathogenic Escherichia coli infection 2/55 0.476 ITGB1, TUBB3
Sulfur metabolism 9/01 0.476 PAPSS2
Leishmaniasis 2/74 0.476 ITGB1, TGFB3
Pancreatic cancer 2/75 0.476 TGFB3, CDKN2A
Chronic myeloid leukemia 2/76 0.476 TGFB3, CDKN2A
Axon guidance 3/181 0.476 SEMA6B, ITGB1, EPHA3

Table 7: KEGG Pathway enrichment result for UF pattern of DEGs.

Keloids and hypertrophic scar specific downregulated DEGs are associated with keratinization, epidermal development, and the estrogen signaling pathway

Compared to upregulated genes, we identified 809 downregulated genes in exaggerated scars such as hypertrophic scars and keloids. Over representation analysis on GO Biological Process terms found most represented terms as ‘keratinization’ and ‘epidermal development’. Also, in KEGG pathways, ‘estrogen signaling pathway’ was the most represented term (Figure 3) (Tables 8 and 9).

diagnostic-pathology-hypertrophic

Figure 3: Differentially Expressed Genes (DEGs) specifically upregulated/downregulated in hypertrophic scars and keloids compared to normotrophic scars. A. DEGs in this group did not differ significantly between hypertrophic scars and keloids but were more upregulated than normotrophic scars. Among the 88 genes, RYR2 (ryanodine receptor 2), ARMC3 (armadillo repeat including 3), and SMCO2 (single-pass membrane protein with coiled-coil domains 2) are representative genes located in the upper rank; B. Genes associated with extracellular structural tissue and extracellular matrix tissues are commonly highly expressed in hypertrophic scars and keloids; C. Unlike the above analysis, DEGs in this group did not differ significantly between hypertrophic scars and keloids as in the previous group, but the expression was lower than that of normotrophic scars. It can be confirmed that almost all of the genes included in the upper rank among the 809 genes are keratin-associated proteins; D. And also it can be seen that they are related to keratinization through GO enrichment analysis.

GO ID Term Overlap Adjusted P-value Genes
GO:0031424 Keratinization 26/47 7.28E-21 SPRR4, SPRR2E, SPRR2F, SPRR2G, TCHH, PPL, EVPL, LCE1A, LCE1B, LCE3D, CASP14, CDH3, SFN, SPRR2A, SPRR2B, TGM3, CNFN, LCE1F, LOR, LCE1C, LCE1D, LCE2B, KRT17, LCE6A, SPRR1A, IVL
GO:0008544 Epidermis development 35/120 1.19E-17 COL17A1, SPRR2E, SPRR2F, SPRR2G, CALML5, BNC1, KLK5, HOXC13, SOX21, EVPL, CST6, KLK7, KRT83, NTF4, CASP14, SOX9, SPRR2A, SPRR2B, DSP, WNT10A, LAMB3, KDF1, KRT34, KRT31, EDAR, ALDH3A2, LCE2B, DCT, KRT17, FABP5, KRT16, KRT15, KRT14, DNASE1L2, SPRR1A
GO:0060429 Epithelium development 42/256 8.96E-12 SPRR2E, RET, COL17A1, SPRR2F, SPRR2G, FOXC1, CALML5, SDC4, BNC1, KLK5, HOXC13, SOX21, EVPL, CST6, KLK7, KRT83, NTF4, CASP14, CECR2, EPCAM, SOX9, SPRR2A, SPRR2B, DSP, TFAP2B, WNT10A, LAMB3, KDF1, KRT34, KRT31, LCE2B, EDAR, ALDH3A2, BMP2, KRT17, FABP5, DCT, KRT16, KRT15, KRT14, DNASE1L2, SPRR1A
GO:0008610 Lipid biosynthetic process 52/491 1.96E-07 SLC44A5, PECR, TECR, MSMO1, TFCP2L1, PLB1, TM7SF2, FADS2, FADS6, SPTLC3, GGT1, GGT2, CERS4, DGAT2, EDN2, ELOVL4, HMGCS1, ACSL1, ELOVL3, CYP39A1, MVD, FAR2, SLC27A2, CFTR, CDS1, ACSS2, MVK, FAXDC2, INSIG1, ABHD5, HMGCR, CYP3A4, HSD17B8, AGPAT3, HSD11B1, HSD17B2, PIP5K1B, SPTSSB, SDR42E1, FDPS, PLA2G2D, GK, SRD5A1, DHCR24, ALOX15B, FABP5, GPAM, FASN, PNPLA3, DHCR7, DEGS2, LPIN3
GO:0044283 Small molecule biosynthetic process 45/394 2.34E-07 CDS1, SLC44A5, PECR, ACSS2, MVK, GLS2, FAXDC2, INSIG1, TECR, GPT, MSMO1, HMGCR, CYP3A4, HSD17B8, TM7SF2, FADS2, IMPA2, FADS6, KYNU, GGT1, GGT2, FDPS, EDN2, ELOVL4, PKLR, HMGCS1, GPT2, ELOVL3, BBOX1, DHCR24, UPB1, CYP4F12, ALOX15B, CYP39A1, GATM, BDH1, FABP5, FASN, PADI3, MVD, DHCR7, SLC27A2, CFTR, LPIN3, BCAT2
GO:0042633 Hair cycle 9/15 5.09E-07 KRT33B, KRTAP4-9, KRTAP4-8, KRTAP4-7, PPP1R13L, KRT16, KRT14, MPZL3, KRT83
GO:0042303 Molting cycle 9/15 5.09E-07 KRT33B, KRTAP4-9, KRTAP4-8, KRTAP4-7, PPP1R13L, KRT16, KRT14, MPZL3, KRT83
GO:1901617 Organic hydroxy compound biosynthetic process 26/166 1.24E-06 CDS1, SLC44A5, PMEL, OCA2, MVK, INSIG1, TYRP1, MSMO1, HMGCR, CYP3A4, TM7SF2, IMPA2, FDPS, GPR37, HMGCS1, BBOX1, DHCR24, TYR, CYP39A1, DCT, FABP5, MVD, DHCR7, SLC27A2, CFTR, LPIN3
GO:0006694 Steroid biosynthetic process 20/108 3.94E-06 SDR42E1, FDPS, MVK, HMGCS1, SRD5A1, INSIG1, MSMO1, DHCR24, TFCP2L1, HMGCR, CYP3A4, HSD17B8, TM7SF2, CYP39A1, HSD11B1, HSD17B2, MVD, DHCR7, SLC27A2, CFTR
GO:1901615 Organic hydroxy compound metabolic process 47/476 5.41E-06 CDS1, SLC44A5, OCA2, PECR, CEBPA, PMEL, ACSS2, MVK, FOXE1, INSIG1, TYRP1, GDPD2, MSMO1, HMGCR, CYP3A4, PLB1, TM7SF2, SDR16C5, PPIP5K1, IMPA2, AWAT2, LRAT, FDPS, PLA2G2D, GPR37, DGAT2, GK, HMGCS1, SORD, BBOX1, DHCR24, TYR, CYP4F12, CYP39A1, ALDH3A2, AKR1B10, FABP5, SOAT1, DCT, PLCH1, MVD, DHCR7, DEGS2, SLC27A2, GPLD1, CFTR, LPIN3

Table 8: GO Biological Process enrichment result for DF pattern of DEGs.

Term Overlap Adjusted P-value Genes
Estrogen signaling pathway 19/137 0.000726 CALML5, TGFA, KRT23, KRT34, CALML3, KRT31, ESR1, KRT33B, KRT33A, KRT18, KRT39, KRT17, KRT16, KRT26, KRT15, KRT36, KRT14, PGR, FKBP5
Terpenoid backbone biosynthesis 6/22 0.0246 FDPS, MVK, HMGCS1, MVD, HMGCR, ACAT2
Steroid biosynthesis 5/19 0.0346 SOAT1, DHCR24, MSMO1, DHCR7, TM7SF2
Glycerolipid metabolism 9/61 0.0346 ALDH3A2, DGAT2, AKR1B10, GK, GPAM, PNPLA3, PNLIPRP3, AGPAT3, LPIN3
Tight junction 17/170 0.0346 MAP3K1, F11R, PRKCZ, CD1A, TIAM1, SLC9A3R1, EPB41L4B, OCLN, CLDN3, MARVELD2, PPP2R2C, CLDN16, EZR, CFTR, LLGL2, TJP2, CRB3
Synthesis and degradation of ketone bodies 10/04 0.0346 BDH1, HMGCS1, OXCT2, ACAT2
ECM-receptor interaction 10/82 0.0653 SDC4, LAMB3, LAMC3, ITGB4, ITGA2, LAMB4, COL4A6, COL4A5, ITGB6, GP6
PPAR signaling pathway 9/74 0.0868 FADS2, GK, FABP5, ACSL1, FABP7, ME1, SLC27A6, ACSBG1, SLC27A2
Steroid hormone biosynthesis 8/60 0.0868 SULT2B1, HSD11B1, SULT1E1, SRD5A1, HSD17B2, UGT1A4, CYP3A4, HSD17B8
Pyruvate metabolism 6/39 0.118 ALDH3A2, ACSS2, PC, PKLR, ME1, ACAT2

Table 9: KEGG Pathway enrichment result for DF pattern of DEGs.

Hypertrophic scar specific genes are associated with epidermal cell differentiation and the lipid catabolic process

Although hypertrophic scars are reversible, the degree of fibrosis is more severe and prolonged compared to that of normotrophic scars. Therefore, we attempted to find hypertrophic scar-specific genes to distinguish them from both keloids and normotrophic scars. Only four DEGs specifically were upregulated in hypertrophic scars, including TUBB2B (tubulin, beta 2B class 2 B), TNFSF4 (tumor necrosis factor superfamily, member 4), TNC (tenascin C), and TNN (tenascin N). In contrast, a total of 237 DEGs was specifically downregulated in hypertrophic scars. Among the mostly changed genes in fold changes, KRTAP5-1 (keratin associated protein 5-1), KRT9 (keratin9), and KRTAP10-6 (keratin associated protein 10-6) are commonly related to keratin. Over-representation analysis results on GO Biological processes revealed that these hypertrophic scar specific expressions were associated with ‘epidermal cell differentiation’, ‘epidermal development’, and ‘water homeostasis. Conversely, over-represented KEGG pathway terms were ‘arachidonic acid metabolism’, ‘linoleic acid metabolism’ (Figure 4) (Tables 10 and 11).

diagnostic-pathology-necrosis

Figure 4: Differentially Expressed Genes (DEGs) specific to hypertrophic scars compared to normotrophic scars and keloids. A. The number of DEGs especially upregulated in hypertrophic scars than in normotrophic scars and keloids, is four, which is TUBB2B (tubulin, beta 2B class llb), TNFSF4 (tumor necrosis factor superfamily, member 4), TNC (tenascin C), TNN (tenascin N); B. A total of 237 DEGs specifically downregulated only in hypertrophic scars. As the top-ranked genes, KRTAP5-1 (keratin associated protein 5-1), KRT9 (keratin9), and KRTAP10-6 (keratin associated protein 10-6) are commonly related to keratin; C. DEGs highly downregulated in hypertrophic scars are related to epidermal cell differentiation and water homeostasis. In addition, arachidonic acid metabolism and linoleic acid metabolism were ranked high in the KEGG pathw ay enrichment analysis.

GO ID Term Overlap Adjusted P-value Genes
GO:0009913 Epidermal cell differentiation 13/76 2.68E-08 CERS3, CSTA, CDSN, SPINK5, OVOL1, POU2F3, FOXN1, TGM1, SCEL, FA2H, ACER1, IRF6, TP63
GO:0050891 Multicellular organismal water homeostasis 9/32 2.27E-07 CDH1, CYP4F2, SCNN1B, SCNN1A, ALOX12B, ABCA12, CLDN1, ALOXE3, TP63
GO:0030104 Water homeostasis 9/38 8.28E-07 CDH1, CYP4F2, SCNN1B, SCNN1A, ALOX12B, ABCA12, CLDN1, ALOXE3, TP63
GO:0030216 Keratinocyte differentiation 10/54 8.88E-07 TGM1, CERS3, SCEL, ACER1, CSTA, CDSN, IRF6, POU2F3, FOXN1, TP63
GO:0008544 Epidermis development 13/120 1.94E-06 TFAP2C, CDSN, GRHL3, KRT5, FOXN1, POU2F3, KRT9, ACER1, SCEL, GJB5, TGM5, SPRR2D, ZNF750
GO:0033561 Regulation of water loss via skin 6/19 5.36E-05 CDH1, ALOX12B, ABCA12, CLDN1, ALOXE3, TP63
GO:0060429 Epithelium development 15/256 0.000325 TFAP2C, CDSN, GRHL3, KRT5, GATA3, FOXN1, POU2F3, KRT9, ACER1, SCEL, GJB5, TGM5, FGFR3, SPRR2D, ZNF750
GO:0006690 Icosanoid metabolic process 9/88 0.000473 CYP2J2;CYP2C9;PLA2G4F;GGT6;PLA2G4B;CYP4F2;CYP4F3;ALOX12B;ALOXE3
GO:0016042 Lipid catabolic process 14/232 0.000488 PLA2G2F, PLA2G4F, PLA2G4D, PLA2G4E, CYP4F2, PLA2G4B, CYP4F3, SMPD3, ACER1, LIPH, LIPM, LIPK, PLCH2, PNPLA1
GO:0061436 Establishment of skin barrier 5/16 0.000507 ALOX12B, ABCA12, CLDN1, ALOXE3, TP63

Table 10: GO Biological Process enrichment result for DU pattern of DEGs.

Term Overlap Adjusted P-value Genes
Arachidonic acid metabolism 11/63 5.66E-08 PLA2G2F, CYP2J2, CYP2C9, PLA2G4F, CYP2B6, PLA2G4D, PLA2G4E, PLA2G4B, CYP4F2, CYP4F3, ALOX12B
Linoleic acid metabolism 7/29 5.78E-06 PLA2G2F, CYP2J2, CYP2C9, PLA2G4F, PLA2G4D, PLA2G4E, PLA2G4B
alpha-Linolenic acid metabolism 5/25 0.00101 PLA2G2F, PLA2G4F, PLA2G4D, PLA2G4E, PLA2G4B
Ovarian steroidogenesis 6/49 0.00183 CYP2J2, PLA2G4F, PLA2G4D, STAR, PLA2G4E, PLA2G4B
Ether lipid metabolism 5/47 0.0141 PLA2G2F, PLA2G4F, PLA2G4D, PLA2G4E, PLA2G4B
Serotonergic synapse 7/113 0.0205 CYP2J2, CYP2C9, PLA2G4F, PLA2G4D, PLA2G4E, PLA2G4B, ALOX12B
Metabolism of xenobiotics by cytochrome P450 5/74 0.0715 ALDH3B2, CYP2C9, CYP2B6, GSTA3, UGT1A6
Sphingolipid metabolism 4/47 0.0787 SMPD3, CERS3, ACER1, SGPP2
Drug metabolism 6/108 0.0801 ALDH3B2, CYP2C9, CYP2B6, GSTA3, XDH, UGT1A6
VEGF signaling pathway 4/59 0.162 PLA2G4F, PLA2G4D, PLA2G4E, PLA2G4B

Table 11: KEGG Pathway enrichment result for DU pattern of DEGs.

Scar-free normal skin is not a proper control group for determining keloid-specific genes

Previous studies have used scar-free normal skin as a control for comparison with keloids. Since keloids are a possible outcome of wound healing, it is uncertain if it is appropriate to compare keloids with unwounded skin tissue. This limitation suggests that documented studies comparing keloids with scar-free normal skin as a control group are including expression profiles of overall scars rather than keloid- specific characteristics. To overcome this issue, we hypothesized that comparing expression profiles between types of scar tissues would find scar subtype specific features better than comparison between keloid and scar-free normal tissue. For scar-free normal comparisons, we imported publicly available normal skin tissue data from GEO (ID: GSE113619). We implemted the same Ensemble approaches on differential expression analysis and identified DEGs. According to over representation analyses with those DEGs, expression profile changes of keloids, hypertrophic scars, and normotrophic scars than normal skin present very similar shared results especially in GO Biological Processes. Specifically, the genes for ‘extracellular matrix/structure organization’ and ‘extracellular matrix assembly’ were upregulated in all three types of scars compared to normal skin. In addition, the genes for ‘keratinization’, ‘epidermal development’, and ‘epithelial cell differentiation’ were downregulated in all three types of scars. These results imply previous studies that directly compared keloids with scar-free normal skin were more likely to discover general scar- specific features rather than keloid-specific features. Therefore, keloid- specific features can be found better by comparing keloids with other reversible scars instead of with scar free normal skin. From these scar tissue type based comparisons, the keloid-specific genes obtained from this improved comparison were related to sensory perception, neuron development, activation of the immune response, and the lipid biosynthetic process (Figure 5) (Tables 12-17).

diagnostic-pathology-keloids

Figure 5: Normotrophic scar, rather than scar free normal skin is ideal for the identification of scar specific DEGs. A. Comparing gene expression profile of normotrophic scars, hypertrophic scars and keloids from the current study against scar free normal skin sample obtained from public database GSE113619; B. Compared with scar free normal skin, the upregulated DEGs in normotrophic scars, hypertrophic scars and keloids respectively overlap. Genes related to extracellular matrix organization, extracellular structure organization and extracellular matrix disassembly were commonly upregulated in DEGs of three scar tissues compared to scar free normal skin. Conversely, DEGs commonly downregulated in each scar tissue are keratinization and epithelial cell differentiation; C. A figure explaining the novelty of the new research strategy, along with the limitations of previous research and the existing research method.

GO ID Term Overlap Adjusted P-value Genes
GO:0030198 Extracellular matrix organization 54/359 1.44E-28 COL14A1, SERPINE1, COL12A1, CYR61, LOXL2, COMP, EFEMP2, ADAMTS2, IBSP, COL10A1, POSTN, EGFL6, MMP1, MMP2, MMP3, FGG, BGN, ADAMTS20, MMP11, VCAN, SFRP2, COL2A1, MMP13, COL4A1, COL6A2, PXDN, COL6A1, COL6A3, MATN3, ENG, FBN2, FOXC2, LAMA2, COL11A1, KLK4, LTBP3, NID2, ACAN, ADAMTS14, ABI3BP, SPP1, TGFB3, FN1, SULF1, SULF2, DSPP, COL1A1, COL1A2, COL5A1, ITGA10, COL5A2, MFAP2, COL20A1, FBN1
GO:0043062 Extracellular structure organization 54/360 1.44E-28 COL14A1, SERPINE1, COL12A1, CYR61, LOXL2, COMP, EFEMP2, ADAMTS2, IBSP, COL10A1, POSTN, EGFL6, MMP1, MMP2, MMP3, FGG, BGN, ADAMTS20, MMP11, VCAN, SFRP2, COL2A1, MMP13, COL4A1, COL6A2, PXDN, COL6A1, COL6A3, MATN3, ENG, FBN2, FOXC2, LAMA2, COL11A1, KLK4, LTBP3, NID2, ACAN, ADAMTS14, ABI3BP, SPP1, TGFB3, FN1, SULF1, SULF2, DSPP, COL1A1, COL1A2, COL5A1, ITGA10, COL5A2, MFAP2, COL20A1, FBN1
GO:0022617 Extracellular matrix disassembly 25/116 3.48E-16 FBN2, COL14A1, COL11A1, COL12A1, KLK4, ACAN, SPP1, COL10A1, MMP1, MMP2, MMP3, FN1, COL1A1, MMP11, COL1A2, COL2A1, MMP13, COL5A1, COL4A1, COL6A2, COL5A2, COL6A1, COL6A3, FBN1, ENG
GO:0044243 Multicellular organismal catabolic process 21/80 2.35E-15 ACE, COL14A1, MMP1, MMP2, COL11A1, COL12A1, MMP3, COL1A1, MMP11, ADAMTS2, ADAMTS14, MMP13, COL2A1, COL1A2, COL5A1, COL4A1, COL6A2, COL6A1, COL5A2, COL10A1, COL6A3
GO:0030574 Collagen catabolic process 20/74 6.36E-15 COL14A1, MMP1, MMP2, COL11A1, COL12A1, MMP3, COL1A1, MMP11, ADAMTS2, ADAMTS14, MMP13, COL2A1, COL1A2, COL5A1, COL4A1, COL6A2, COL6A1, COL5A2, COL10A1, COL6A3
GO:0044259 Multicellular organismal macromolecule metabolic process 21/89 1.72E-14 ACE, COL14A1, MMP1, MMP2, COL11A1, COL12A1, MMP3, COL1A1, MMP11, ADAMTS2, ADAMTS14, MMP13, COL2A1, COL1A2, COL5A1, COL4A1, COL6A2, COL6A1, COL5A2, COL10A1, COL6A3
GO:0044236 Multicellular organismal metabolic process 21/94 4.69E-14 ACE, COL14A1, MMP1, MMP2, COL11A1, COL12A1, MMP3, COL1A1, MMP11, ADAMTS2, ADAMTS14, MMP13, COL2A1, COL1A2, COL5A1, COL4A1, COL6A2, COL6A1, COL5A2, COL10A1, COL6A3
GO:0032963 Collagen metabolic process 20/83 4.69E-14 COL14A1, MMP1, MMP2, COL11A1, COL12A1, MMP3, COL1A1, MMP11, ADAMTS2, ADAMTS14, MMP13, COL2A1, COL1A2, COL5A1, COL4A1, COL6A2, COL6A1, COL5A2, COL10A1, COL6A3
GO:0030199 Collagen fibril organization 15/41 2.55E-13 FOXC2, COL14A1, COL11A1, COL12A1, LOXL2, COL1A1, ACAN, MMP11, ADAMTS14, ADAMTS2, COL1A2, COL2A1, SFRP2, COL5A1, COL5A2
GO:0001501 Skeletal system development 19/162 1.49E-07 POSTN, COL12A1, IGF2, AEBP1, SULF1, PAPSS2, PAX1, SULF2, DSPP, COMP, COL1A1, ACAN, COL1A2, COL2A1, COL5A2, COL10A1, ARSE, MATN3, FBN1

Table 12: GO Biological Process enrichment result for up regulated DEGs in Normotrophic Scar VS. Normal (GSE113619).

GO ID Term Overlap Adjusted P-value Genes
GO:0031424 Keratinization 12/47 3.08E-07 LCE1A, LCE2B, LCE1B, LCE4A, LCE6A, LCE1E, EVPL, LCE1F, LCE2D, LOR, LCE1C, LCE1D
GO:0030182 Neuron differentiation 15/222 0.0461 BCL11B, WNT3A, WNT7B, WNT9B, WNT7A, RORA, WNT16, GDF7, NTF4, NGRN, ID4, FGFR3, WNT3, HES5, WNT4
GO:0009611 Response to wounding 13/167 0.0461 SERPINB2, PLLP, TGFA, NMNAT3, KLK8, POU2F3, EREG, RTN4RL1, CYP1A1, BCL2, TSPO, FGFR3, MATN4
GO:0045165 Cell fate commitment 11/134 0.0608 WNT3A, WNT7B, BCL2, WNT9B, WNT7A, WNT16, FGFR3, WNT3, HES5, WNT4, GDF7
GO:0060429 Epithelium development 15/256 0.131 CALML5, SDC4, WNT7B, KDF1, KLK5, FOXJ1, EVPL, POU2F3, POU3F3, LCE2B, NTF4, FGFR3, WNT3, HES5, WNT4
GO:0035588 G-protein coupled purinergic receptor signaling pathway 4/17 0.131 ADORA2A, P2RY2, P2RY1, ADORA1
GO:0061098 Positive regulation of protein tyrosine kinase activity 5/32 0.131 WNT3A, DOK7, ADORA1, TGFA, EREG
GO:0014014 Negative regulation of gliogenesis 5/32 0.131 ID4, TSPO, ASCL2, FGFR3, HES5
GO:0022010 Central nervous system myelination 9/03 0.131 ID4, FGFR3, HES5
GO:0060428 Lung epithelium development 9/03 0.131 WNT7B, FOXJ1, FGFR3

Table 13: GO Biological Process enrichment result for down regulated DEGs in Normotrophic Scar VS Normal (GSE113619).

GO ID Term Overlap Adjusted P-value Genes
GO:0030198 Extracellular matrix organization 71/359 8.08E-37 OLFML2B, COL14A1, ELN, SERPINE1, COL12A1, TNC, SCX, PLOD2, PLOD1, CYR61, LOXL2, COMP, ADAMTS4, EFEMP2, ADAMTS2, IBSP, SH3PXD2B, COL10A1, POSTN, EGFL6, MMP2, BGN, HSPG2, ADAMTS20, MMP11, VCAN, SFRP2, COL2A1, MMP13, COL4A1, COL6A2, PXDN, COL6A1, COL8A1, COL6A3, MATN3, ENG, FBN2, FOXC2, LAMA2, COL11A1, LAMA4, KLK4, LTBP3, NID2, ACAN, ADAMTS14, ABI3BP, SPP1, TGFB1, COL24A1, TGFB3, LUM, FN1, LAMB1, SULF1, GDF5, SULF2, DSPP, COL1A1, COL3A1, COL1A2, BMP1, COL5A1, WT1, ITGA10, COL5A2, ITGA11, MFAP2, TLL2, FBN1
GO:0043062 Extracellular structure organization 71/360 8.08E-37 OLFML2B, COL14A1, ELN, SERPINE1, COL12A1, TNC, SCX, PLOD2, PLOD1, CYR61, LOXL2, COMP, ADAMTS4, EFEMP2, ADAMTS2, IBSP, SH3PXD2B, COL10A1, POSTN, EGFL6, MMP2, BGN, HSPG2, ADAMTS20, MMP11, VCAN, SFRP2, COL2A1, MMP13, COL4A1, COL6A2, PXDN, COL6A1, COL8A1, COL6A3, MATN3, ENG, FBN2, FOXC2, LAMA2, COL11A1, LAMA4, KLK4, LTBP3, NID2, ACAN, ADAMTS14, ABI3BP, SPP1, TGFB1, COL24A1, TGFB3, LUM, FN1, LAMB1, SULF1, GDF5, SULF2, DSPP, COL1A1, COL3A1, COL1A2, BMP1, COL5A1, WT1, ITGA10, COL5A2, ITGA11, MFAP2, TLL2, FBN1
GO:0022617 Extracellular matrix disassembly 32/116 2.68E-20 FBN2, COL14A1, ELN, COL11A1, COL12A1, KLK4, ADAMTS4, ACAN, SH3PXD2B, SPP1, COL10A1, MMP2, FN1, LAMB1, HSPG2, COL1A1, MMP11, COL3A1, COL1A2, BMP1, COL2A1, MMP13, COL5A1, COL4A1, COL6A2, COL5A2, COL6A1, COL8A1, COL6A3, TLL2, FBN1, ENG
GO:0030199 Collagen fibril organization 18/41 5.93E-15 FOXC2, COL14A1, LUM, COL11A1, COL12A1, SCX, LOXL2, COL1A1, ACAN, MMP11, ADAMTS14, ADAMTS2, COL3A1, COL1A2, COL2A1, SFRP2, COL5A1, COL5A2
GO:0001501 Skeletal system development 29/162 6.02E-13 HOXD1, COL12A1, SCX, AEBP1, PHEX, PAPSS2, COMP, ADAMTS4, ACAN, SH3PXD2B, COL10A1, ARSE, POSTN, DMRT2, IGF2, SULF1, PAX1, SULF2, DSPP, COL1A1, COL3A1, COL1A2, BMP1, COL2A1, COL5A2, CDH11, ALPL, MATN3, FBN1
GO:0044243 Multicellular organismal catabolic process 21/80 1.50E-12 ACE, COL14A1, MMP2, COL11A1, COL12A1, COL1A1, MMP11, ADAMTS2, ADAMTS14, COL3A1, MMP13, COL2A1, COL1A2, COL5A1, COL4A1, COL6A2, COL6A1, COL5A2, COL10A1, COL8A1, COL6A3
GO:0030574 Collagen catabolic process 20/74 3.19E-12 COL14A1, MMP2, COL11A1, COL12A1, COL1A1, MMP11, ADAMTS2, ADAMTS14, COL3A1, MMP13, COL2A1, COL1A2, COL5A1, COL4A1, COL6A2, COL6A1, COL5A2, COL10A1, COL8A1, COL6A3
GO:0001503 Ossification 24/116 3.93E-12 FOXC2, ECM1, TGFB1, TGFB3, MMP2, BMP8A, SCX, CHRDL2, HSPG2, RUNX2, CTGF, DSPP, COL1A1, IGSF10, MN1, BMP1, COL2A1, MMP13, CDH11, GNAS, SPP1, ALPL, COL10A1, CTHRC1
GO:0044259 Multicellular organismal macromolecule metabolic process 21/89 1.02E-11 ACE, COL14A1, MMP2, COL11A1, COL12A1, COL1A1, MMP11, ADAMTS2, ADAMTS14, COL3A1, MMP13, COL2A1, COL1A2, COL5A1, COL4A1, COL6A2, COL6A1, COL5A2, COL10A1, COL8A1, COL6A3
GO:0032963 Collagen metabolic process 20/83 2.46E-11 COL14A1, MMP2, COL11A1, COL12A1, COL1A1, MMP11, ADAMTS2, ADAMTS14, COL3A1, MMP13, COL2A1, COL1A2, COL5A1, COL4A1, COL6A2, COL6A1, COL5A2, COL10A1, COL8A1, COL6A3

Table 14: GO Biological Process enrichment result for up regulated DEGs in Hypertrophic Scar VS. Normal (GSE113619).

GO ID Term Overlap Adjusted P-value Genes
GO:0031424 Keratinization 30/47 4.70E-21 SPRR2E, ABCA12, PPL, EVPL, LCE2D, TGM1, LCE1A, LCE1B, LCE3D, CASP14, LCE5A, SFN, TGM3, SPRR2D, KRT2, CNFN, LCE1E, LCE1F, LOR, LCE1C, LCE3E, LCE1D, LCE2B, LCE2C, LCE2A, KRT17, LCE4A, LCE6A, SPRR1B, IVL
GO:0008544 Epidermis development 42/120 2.90E-17 COL17A1, SPRR2E, CALML5, BNC1, KLK5, HOXC13, SOX21, EVPL, CST6, KLK7, NTF4, CASP14, SCEL, ALX4, TGM5, SPRR2D, DSP, TFAP2C, WNT10A, CDSN, LAMB3, KRT2, KDF1, GRHL3, KRT5, KRT31, FOXN1, POU2F3, KRT9, EDAR, LCE2B, ACER1, ELF3, DCT, KRT17, KRT16, KRT15, GJB5, KRT14, DNASE1L2, SPRR1B, ZNF750
GO:0050891 Multicellular organismal water homeostasis 19/32 3.93E-12 FLG, CYP4F2, KRT1, KDF1, ALOX12B, ALOX12, ABCA12, CLDN1, CYP4F12, FLG2, SCNN1G, CLDN4, CDH1, SCNN1B, TMEM79, SCNN1A, SFN, ALOXE3, TP63
GO:0030104 Water homeostasis 20/38 1.32E-11 FLG, CYP4F2, AQP9, KRT1, KDF1, ALOX12B, ALOX12, ABCA12, CLDN1, CYP4F12, FLG2, SCNN1G, CLDN4, CDH1, SCNN1B, TMEM79, SCNN1A, SFN, ALOXE3, TP63
GO:0060429 Epithelium development 52/256 7.04E-11 CALML5, BNC1, HOXC13, SOX21, CASP14, TGM5, DSP, KRT2, KRT5, KRT31, POU3F3, KRT9, LCE2B, EDAR, SFRP1, ELF3, DCT, DNASE1L2, ZNF750, SPRR2E, COL17A1, SDC4, KLK5, GATA3, EVPL, CST6, KLK7, NTF4, SCEL, ALX4, WNT3, HES5, SPRR2D, WNT4, WNT10A, TFAP2C, CDSN, LAMB3, WNT7B, KDF1, FOXJ1, GRHL3, FOXN1, POU2F3, ACER1, KRT17, KRT16, KRT15, GJB5, KRT14, FGFR3, SPRR1B
GO:0061436 Establishment of skin barrier 13/16 8.84E-11 FLG, KRT1, KDF1, ALOX12B, ALOX12, ABCA12, CLDN1, FLG2, CLDN4, TMEM79, SFN, ALOXE3, TP63
GO:0033561 Regulation of water loss via skin 14/19 8.87E-11 FLG, KRT1, KDF1, ALOX12B, ALOX12, ABCA12, CLDN1, FLG2, CLDN4, CDH1, TMEM79, SFN, ALOXE3, TP63
GO:0009913 Epidermal cell differentiation 25/76 1.99E-09 FLG, CSTA, EVPL, TGM1, SCEL, TGM3, TP63, HES5, DSP, CERS3, ST14, CDSN, SPINK5, KRT10, POU3F1, OVOL1, POU2F3, FOXN1, LOR, EREG, FA2H, ACER1, IRF6, IVL, SPRR1B
GO:0030216 Keratinocyte differentiation 21/54 2.27E-09 DSP, CERS3, FLG, CSTA, ST14, CDSN, KRT10, POU3F1, EVPL, POU2F3, FOXN1, LOR, EREG, TGM1, SCEL, ACER1, IRF6, TGM3, TP63, IVL, SPRR1B
GO:0030855 Epithelial cell differentiation 53/303 9.18E-09 EHF, CTSV, F11R, SYNE4, TGM1, UPK1B, TP63, TGM3, CERS3, DSP, CBR1, MREG, KRT4, TCF15, SPINK5, OVOL1, POU3F1, KLF15, LOR, EREG, ELF3, TST, ELF5, ALDOC, IRF6, RHCG, IVL, FLG, OCA2, CSTA, DLX3, TYRP1, EVPL, SCEL, AGR2, HES5, SPDEF, WNT4, ST14, CDSN, PTK6, KRT10, FOXN1, POU2F3, GDF7, FA2H, ACER1, KRT16, KRT14, CYP1A1, BCL2, CD24, SPRR1B

Table 15: GO Biological Process enrichment result for down regulated DEGs in Hypertrophic Scar VS. Normal (GSE113619).

GO ID Term Overlap Adjusted P-value Genes
GO:0030198 Extracellular matrix organization 75/359 4.56E-30 COL16A1, OLFML2B, COL14A1, SERPINE1, COL12A1, SCX, PLOD2, PLOD1, CYR61, LOXL2, COMP, ADAMTS4, EFEMP2, ADAMTS2, IBSP, SH3PXD2B, COL10A1, FGA, POSTN, COL27A1, EGFL6, MMP2, BGN, HSPG2, ADAMTS20, MMP11, VCAN, SFRP2, COL2A1, MMP13, COL6A2, PXDN, COL6A1, COL8A1, COL6A3, COL6A6, MATN3, ENG, FBN2, FOXC2, LAMA1, COL11A1, COL11A2, KLK4, LTBP3, NID2, ACAN, ADAMTS14, ABI3BP, TGFB1, COL24A1, FOXF2, FOXF1, TGFB3, LUM, FN1, SULF1, GDF5, AGT, SULF2, DSPP, COL1A1, COL3A1, COL1A2, BMP1, COL5A1, NPHS1, ITGA10, COL5A2, ITGA11, MFAP2, COL9A1, COL20A1, TLL2, FBN1
GO:0043062 Extracellular structure organization 75/360 4.56E-30 COL16A1, OLFML2B, COL14A1, SERPINE1, COL12A1, SCX, PLOD2, PLOD1, CYR61, LOXL2, COMP, ADAMTS4, EFEMP2, ADAMTS2, IBSP, SH3PXD2B, COL10A1, FGA, POSTN, COL27A1, EGFL6, MMP2, BGN, HSPG2, ADAMTS20, MMP11, VCAN, SFRP2, COL2A1, MMP13, COL6A2, PXDN, COL6A1, COL8A1, COL6A3, COL6A6, MATN3, ENG, FBN2, FOXC2, LAMA1, COL11A1, COL11A2, KLK4, LTBP3, NID2, ACAN, ADAMTS14, ABI3BP, TGFB1, COL24A1, FOXF2, FOXF1, TGFB3, LUM, FN1, SULF1, GDF5, AGT, SULF2, DSPP, COL1A1, COL3A1, COL1A2, BMP1, COL5A1, NPHS1, ITGA10, COL5A2, ITGA11, MFAP2, COL9A1, COL20A1, TLL2, FBN1
GO:0022617 Extracellular matrix disassembly 32/116 1.23E-15 FBN2, COL16A1, COL14A1, COL11A1, COL12A1, COL11A2, KLK4, ADAMTS4, ACAN, SH3PXD2B, COL10A1, MMP2, FN1, HSPG2, COL1A1, MMP11, COL3A1, COL1A2, BMP1, COL2A1, MMP13, COL5A1, COL6A2, COL5A2, COL6A1, COL9A1, COL8A1, COL6A3, TLL2, COL6A6, FBN1, ENG
GO:0030199 Collagen fibril organization 19/41 1.59E-13 FOXC2, COL14A1, LUM, COL11A1, COL12A1, COL11A2, SCX, LOXL2, COL1A1, ACAN, MMP11, ADAMTS14, ADAMTS2, COL3A1, COL1A2, COL2A1, SFRP2, COL5A1, COL5A2
GO:0044243 Multicellular organismal catabolic process 25/80 1.76E-13 COL16A1, COL14A1, PLA2G1B, COL11A1, COL12A1, COL11A2, ADAMTS2, ADAMTS14, COL10A1, ACE, MMP2, COL1A1, MMP11, COL3A1, MMP13, COL2A1, COL1A2, COL5A1, COL6A2, COL6A1, COL5A2, COL9A1, COL8A1, COL6A3, COL6A6
GO:0030574 Collagen catabolic process 23/74 2.63E-12 COL16A1, COL14A1, MMP2, COL11A1, COL12A1, COL11A2, COL1A1, MMP11, ADAMTS2, ADAMTS14, COL3A1, MMP13, COL2A1, COL1A2, COL5A1, COL6A2, COL6A1, COL5A2, COL9A1, COL10A1, COL8A1, COL6A3, COL6A6
GO:0044236 Multicellular organismal metabolic process 25/94 8.37E-12 COL16A1, COL14A1, PLA2G1B, COL11A1, COL12A1, COL11A2, ADAMTS2, ADAMTS14, COL10A1, ACE, MMP2, COL1A1, MMP11, COL3A1, MMP13, COL2A1, COL1A2, COL5A1, COL6A2, COL6A1, COL5A2, COL9A1, COL8A1, COL6A3, COL6A6
GO:0044259 Multicellular organismal macromolecule metabolic process 24/89 1.75E-11 COL16A1, ACE, COL14A1, MMP2, COL11A1, COL12A1, COL11A2, COL1A1, MMP11, ADAMTS2, ADAMTS14, COL3A1, MMP13, COL2A1, COL1A2, COL5A1, COL6A2, COL6A1, COL5A2, COL9A1, COL10A1, COL8A1, COL6A3, COL6A6
GO:0032963 Collagen metabolic process 23/83 2.79E-11 COL16A1, COL14A1, MMP2, COL11A1, COL12A1, COL11A2, COL1A1, MMP11, ADAMTS2, ADAMTS14, COL3A1, MMP13, COL2A1, COL1A2, COL5A1, COL6A2, COL6A1, COL5A2, COL9A1, COL10A1, COL8A1, COL6A3, COL6A6
GO:0001501 Skeletal system development 31/162 7.58E-11 HOXD1, COL12A1, COL11A2, SCX, AEBP1, PHEX, PAPSS2, GLI2, COMP, ADAMTS4, RAI1, ACAN, SH3PXD2B, COL10A1, SPP2, ARSE, POSTN, IGF2, SULF1, PAX1, SULF2, DSPP, COL1A1, COL3A1, COL1A2, BMP1, COL2A1, COL5A2, CDH11, MATN3, FBN1

Table 16: GO Biological Process enrichment result for up regulated DEGs in Keloid VS. Normal (GSE113619).

GO ID Term Overlap Adjusted P-value Genes
GO:0031424 Keratinization 21/47 2.80E-11 KRT2, CNFN, LCE1E, PPL, EVPL, LCE1F, LCE2D, LOR, LCE1C, LCE3E, LCE1D, LCE1A, LCE2B, LCE1B, LCE2C, LCE2A, LCE5A, LCE4A, LCE6A, SFN, TGM3
GO:0008544 Epidermis development 29/120 1.33E-08 COL17A1, CALML5, BNC1, KLK5, SOX21, EVPL, CST6, KLK7, NTF4, SCEL, TGM5, DSP, TFAP2C, WNT10A, LAMB3, KRT2, KDF1, GRHL3, KRT5, POU2F3, EDAR, LCE2B, ACER1, ELF3, DCT, KRT15, GJB5, KRT14, DNASE1L2
GO:0060429 Epithelium development 38/256 2.21E-05 COL17A1, CALML5, SDC4, BNC1, KLK5, SOX21, EVPL, CST6, KLK7, NTF4, SCEL, TGM5, WNT3, HES5, WNT4, DSP, WNT10A, TFAP2C, LAMB3, KRT2, KDF1, FOXJ1, GRHL3, KRT5, POU2F3, POU3F3, LCE2B, EDAR, ACER1, SFRP1, ELF3, DCT, KRT15, GJB5, KRT14, SDC1, DNASE1L2, FGFR3
GO:0016338 Calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules 8/22 0.0103 CLDN10, CLDN4, CLDN3, CLDN8, CLDN23, CLDN7, CLDN16, CLDN1
GO:0006582 Melanin metabolic process 12/06 0.0103 PMEL, DCT, TYRP1, ASIP, BCL2, TYR
GO:0006694 Steroid biosynthetic process 18/108 0.0103 SDR42E1, HMGCS1, SRD5A1, DHCR24, TFCP2L1, HSD17B8, TM7SF2, CYP39A1, HSD11B1, CYB5R1, STAR, HSD17B1, TSPO, MVD, DHCR7, HMGCS2, SLC27A2, WNT4
GO:0003334 Keratinocyte development 8/05 0.0103 TFAP2C, BCL11B, KDF1, SFN, EXPH5
GO:0030855 Epithelial cell differentiation 35/303 0.0103 EHF, DLX3, TYRP1, CTSV, F11R, EVPL, SCEL, TGM3, HES5, SPDEF, WNT4, CERS3, DSP, CBR1, ST14, MREG, PTK6, OVOL1, POU3F1, POU2F3, KLF15, LOR, EREG, GDF7, ACER1, DHRS9, ELF3, TST, ELF5, KRT14, BCL2, ALDOC, IRF6, CD24, RHCG
GO:0030216 Keratinocyte differentiation 12/54 0.0103 DSP, CERS3, SCEL, ACER1, ST14, IRF6, POU3F1, EVPL, POU2F3, TGM3, LOR, EREG
GO:1901617 Organic hydroxy compound biosynthetic process 23/166 0.0126 CDS1, PMEL, GPR37, HMGCS1, TYRP1, ASIP, BBOX1, ALOX12, DHCR24, TYR, TM7SF2, CYP39A1, CYB5R1, ACER1, STAR, DCT, IMPA2, HSD17B1, LEP, MVD, DHCR7, HMGCS2, SLC27A2

Table 17: GO Biological Process enrichment result for down regulated DEGs in Keloid VS. Normal (GSE113619).

Discussion

In this study, to identify keloid-specific gene expression profiles, keloid tissues were compared with reversible scar tissues using whole transcriptome analysis. In addition, hypertrophic scar-specific genes were determined. Our present study suggests that peripheral development and immune regulation-related genes are involved in the pathogenesis of keloids. To the best of our knowledge, no such results have been reported previously.

The wound repair process has several phases: The (1) inflammatory phase, (2) proliferative phase, and (3) remodeling phase [31-33]. In the first step, activation of platelets and the clotting cascade cause blood clotting and immobilization of platelets at the wound site. Then inflammatory cells are recruited to the wound site. During the proliferation phase, fibroblasts are activated and differentiated into myofibroblast-producing and organizing ECM molecules, activating the process of re-epithelialization. Finally, during the remodeling (maturation) phase, collagen fibers are remodeled, and excessive fibroblasts are removed by apoptosis.

We confirmed that the expression of genes related to extracellular matrix organization and disassembly was highly expressed in hypertrophic scars and keloids compared to scar free normal skin tissue based on the analysis of GO biological process and KEGG pathway, as well as elevated expression of genes related to regulation of neuron differentiation and expression. It should be noted that the high expression of genes related to muscle filament sliding and actin-myosin filament sliding was observed only in keloids.

When comparing scars that have undergone such a wound healing process with healthy normal skin tissue, wound healing-related genes were discovered preferentially as DEGs rather than genes unique to each scar. Indeed, our present study revealed that scar-free normal skin is an inappropriate control group for determining a unique gene-set for any type of scar. Therefore, we compared keloids, as an irreversible scar, with reversible scars that had undergone the same wound healing process as keloids.

Of the keloid-specific genes discovered by comparison with reversible scars, the Golgin A6 family and ERICH6B were prominent in terms of both fold-change and p-value. The Golgin A6 family is a type of coiled-coil protein located in the Golgi apparatus, called golgin [30]. Although the function of the Golgin A6 family is not known, the major functions of related golgins have been determined. Golgin protein maintains the Golgi architecture, is responsible for vesicular traffic, and plays a role in intracellular signal modulation. Since one of the distinguishing characteristics of keloids is the formation of collagen bundles through hypersecretion of collagen, the golgin family which is involved in the intracellular transport of collagen, is highly likely to be a keloid-specific marker. These results are supported other studies comparing keloids and scar-free normal skin (Supplementary Figures 1 and 2). Although little is known about ERICH6B, it is highly expressed in hypersecretory fibroblasts found in various lesions of the skin [34]. This result also is supported by other studies that have discovered keloid-specific genes.

To further dissect the pathogenesis of keloids, we conducted ORA to identify keloid specifically activated or inactivated pathways. By comparing keloids with reversible scars, we discovered that ‘visual/ sensory perception’ and ‘response to corticosteroids’ were highly specific and upregulated pathways for keloids. Interestingly, common symptoms of keloids are itching and pain, both of which are associated directly or indirectly with ‘visual/sensory perception.’ In addition, corticosteroid injections or ointments have been determined to be effective treatments for keloids, which is highly consistent with our findings [35].

Another finding of our present study is that genes related to ‘activation of immune response,’ ‘antigen processing and presentation of peptide antigen,’ ‘B cell mediated immunity,’ and the ‘regulation of T cell activation’ were downregulated specifically in keloids. In line with these findings, several studies have underscored the role of the immune cell population in keloids. Jaclyn, et al. reported that CD20+ and CD19+ B cells were significantly increased in keloid tissue compared to normal skin [36]. Murao, et al reported that coculture of keloid fibroblasts with T cell populations enhanced collagen synthesis within fibroblasts [37]. Chen, et al, reported that Treg-associated gene expression was significantly higher in keloids compared to normal skin, which is in agreement with our results [38]. These findings suggest a connection between immune cells and keloids. However, further research is required to validate this suggestion.

Although hypertrophic scars are milder than keloids, they are frequently accompanied by a number of esthetics, functional, and social impairments that can lead to decreased quality of life [39]. Therefore, it is valuable to discover hypertrophic scar-specific gene sets to help in understanding the etiology of hypertrophic scars. As illustrated in Figure 4, a total of 241 HS-specific genes was discovered and is involved in lipid metabolism and water homeostasis. Interestingly, the significance of lipid metabolism in scar formation and wound healing was highlighted in several studies by Louw [40-43]. Proper epidermal hydration is essential for homeostasis of the skin based on the differentiation of epidermal keratinocytes and dermal fibroblasts and modulation of the inflammatory phase [44,45]. Interestingly, in dermatologic treatment, hydration is a recommended method for patients with hypertrophic scars [46].

Conclusions

In this study, using more accurate controls of hypertrophic and normotrophic scars, we discovered keloid-specific pathways and genes. The results of our present study strongly suggest that immune cell immunity and sensory perception are involved in the pathogenesis of keloids. Furthermore, our present study contributed to the understanding of keloid pathogenesis by providing potential biomarkers of keloids such as the golgin A6 family and ERICH6B. Extracellular matrix-related processes were also highlighted in both hypertrophic scars and keloids. Finally, we highlight potential keloid- specific biomarkers and expression changes that could be used in future keloids therapeutics.

Acknowledgements

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (grant number: 2019R1A2C2003900, 2016R1A5A2945889). This research was also supported by the Bio & Medical Technology Development Program of the National Research Foundation of Korea (NRF) funded by the Ministry of Science & ICT(grant number : 2020M3E5E2040308).

Author Information

All authors helped conceive and design the study and develop the hypothesis. Y.O. and E.L. conducted the laboratory experiment. J.L. conducted the data analysis. J.L, K.M. and M.C. analyzed and interpreted the data and wrote the manuscript. J.H.L and S.H.K. designed experiments, supervised the study.

Data Availability

RNA-seq data that support the findings of this study have been deposited in the GEO under accession number GSE188952. All other relevant data supporting the main findings of this study are available from the corresponding authors upon reasonable request.

Competing Interests

The authors declare no competing interests.

Author's Contribution

Yoojeong Oh and Jaemyun Lyu contributed to this paper equally.

References

Citation: Oh Y, Lyu J, Muthuramalingam K, Lee E, Choi M, et al. (2022) Keloid- specific Gene Expression Profiling for Accurate Diagnostic and Therapeutic Applications. Diagnos Pathol Open 7:003. DOI: 10.4172/ 2476-2024.7.S12.003

Copyright: © 2022 Oh Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top